

Accepted Manuscript

Title: To be boosted or not to be boosted: more evidence based on cohort study needed

Authors: Chunfeng Qu, Yuting Wang, Chunsun Fan

PII: S1201-9712(17)30284-9
DOI: <https://doi.org/10.1016/j.ijid.2017.11.002>
Reference: IJID 3081

To appear in: *International Journal of Infectious Diseases*

Received date: 6-11-2017
Accepted date: 6-11-2017

Please cite this article as: Qu Chunfeng, Wang Yuting, Fan Chunsun. To be boosted or not to be boosted: more evidence based on cohort study needed. *International Journal of Infectious Diseases* <https://doi.org/10.1016/j.ijid.2017.11.002>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



To be boosted or not to be boosted: more evidence based on cohort study needed

Chunfeng Qu¹, Yuting Wang¹, Chunsun Fan² and ??

1. Department of Immunology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
2. Department of Etiology, Qidong People's Hospital/Qidong Liver Cancer Institute, Jiangsu 226200, China

Correspondence to: Professor Chunfeng Qu: quchf@cicams.ac.cn

Or ??

Summary:

To control the infection of hepatitis B virus (HBV) plasma-derived hepatitis B vaccine, the first generation vaccine, was administrated to millions of infants. In addition, due to various reasons, the HBIG was not administrated to the high-risk infants who were born to HBsAg-positive mother in many low- and middle-income countries and areas. Nowadays, plasma-derived hepatitis B vaccine was totally replaced by recombinant HBV vaccines and most of the high-risk infants were immunized together with HBIG administration. As the population who were vaccinated with plasma-derived hepatitis B vaccine stepped into their third decades, we could get some experiences from them by monitoring the HBV serological markers.

Download English Version:

<https://daneshyari.com/en/article/8739128>

Download Persian Version:

<https://daneshyari.com/article/8739128>

[Daneshyari.com](https://daneshyari.com)